Whereas our microarray studies indicated the expression of IL-33 may be important for cancer development, the involvement of the immune response in limiting prostate cancer and potential effectiveness of immunotherapeutic approaches in decreasing cancer recurrence is still widely debated in the literature. The gene discussed is IL33; the disease is Familial prostate cancer.